When, if ever, would you recommend risk reducing BSO in patients with moderate penetrance breast cancer germline mutations?

RAD51C, RAD51D, and BRIP1 are all associated with significant risks of ovarian cancer and are appropriate for consideration of prophylactic oophorectomy, albeit perhaps at a slightly later age than BRCA1 and BRCA2. ATM and PALB2 may be associated with ovarian cancer risks that are similar to that of...

While the risk of ovarian cancer with those mutations is not as high as for BRCA1, there does seem to be some risk. We also need to remember that RR BSO prior to menopause also reduces the risk of breast cancer. I would consider RR BSO in those patients whenever they have completed childbearing, max...